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ABSTRACT 
Background: Antipsychotic drugs for the treatment ofschizophrenia provide 
effective treatment of psychotic symptoms but might lead to neuroendocrine 
abnormalities. 
Objective: The aim of this study was to assess hypothalamic-pituitary-gonadal 
(HPG) axis function by comparing serum hormone profiles of newly admitted 
patients with psychotic disorders who were receiving antipsychotic drugs with 
those who were antipsychotic-drug-free during the preceding 6 months. 
Methods: Adult male patients admitted uring a 1-year period (December 
1999 to December 2000) to 1 of 2 Brazilian public psychiatric inpatient units that 
provide care for severely ill patients were eligible for this cross-sectional study 
if they had a diagnosis of schizophrenia based on the criteria given in the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and a score 
>24 on the Brief Psychiatric Rating Scale. On the morning after admission, 
serum concentrations f follicle-stimulating hormone (FSH), luteinizing hor- 
mone (LH), sex hormone-binding globulin (SHBG), prolactin, free testosterone 
(FT), and total testosterone (TT) were determined. A commercial laboratory 
provided the normal serum hormone concentrations of healthy Brazilian men 
in the same age range as that of the study patients. 
Results: Sixty-three adult male patients, aged 18 to 55, were included in the 
study. Forty-eight (76.2%) patients (mean [SD] age, 30.6 [8.9] years) were receiv- 
ing antipsychotic drugs (treated). Fifteen (23.8%) patients (mean [SD] age, 
36.5 [9.8] years) were antipsychotic-drug-free for 6 months before admission 
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(untreated). The only significant between-group difference was for disease 
duration (treated, 7.6 [8.1] years vs untreated, 12.3 [9.7] years; P = 0.044). 
Treated patients were more likely to have higher dispersed serum hormone 
concentrations than the untreated patients. Serum concentration of FSH was 
numerically higher in the treated patients than in the untreated patients, 
although the difference was not statistically significant. Compared with the con- 
trol group (1436 men and women for prolactin; 226 men for LH; 207 for FSH; 
128 for TT; 128 for FT; and 128 for SHBG), patients in the treated group had sig- 
nificantly different mean [SD] serum concentrations of all hormones (treated vs 
control: prolactin, 24.3 [23.7] 1Jg/L vs 6.8 [0.12] 1Jg/L, P< 0.001; LH, 4.9 [3.4] U/L 
vs 3.3 [0.13] U/L, P = 0.001; FSH, 4.4 [3.9] U/L vs 3.0 [0.06] U/L, P = 0.025; TT, 
17.5 [7.8] nmol/L vs 20.1 [1.64] nmol/L, P = 0.004; FT, 0.056 [0.08] nmol/L vs 
0.06 [0.003] nmol/L, P< 0.001; and SHBG, 33.3 [18.9] nmol/L vs 48.4 [1.45] nmol/L, 
P = 0.002). Compared with the control group, patients in the untreated group had 
significantly different mean (SD) serum concentrations of all hormones except 
FSH and TT (untreated vs control: prolactin, 19.9 [12.8] 1Jg/L vs 6.8 [0.12] 1Jg/L, 
P = 0.001; LH, 6.0 [1.9] U/L vs 3.3 [0.13] U/L, P = 0.002; FT, 0.08 [0.04] nmol/L vs 
0.06 [0.003] nmol/L, P= 0.001; and SHBG, 26.6 [11.6] nmol/L vs 48.4 [1.45] nmol/L, 
P < 0.001). No differences were found between the TT distribution curve of the 
control group and that of the untreated patients. 
Conclusion: This study supports further investigation of a potential differ- 
ence in the HPG axis among treated and untreated patients with schizophrenia 
and those who do not have that condition. (Curr Ther Res Clin Exp. 2006;67: 
350-363) Copyright © 2006 Excerpta Medica, Inc. 
Key words: prolactin, hormone profile, schizophrenia, psychotic disorders, 
antipsychotics. 
INTRODUCTION 
The onset of schizophrenia atthe beginning of or during the reproductive y ars 
suggests that the disorder might be associated with cerebral and physiologic 
changes that begin in adolescence. In a study performed by Van Cauter et al, 1 
plasma levels of prolactin, growth hormone, corticotropin, and cortisol were 
measured at 15-minute intervals for 24 hours in 9 unmedicated schizophrenic 
male patients and in 9 age-matched normal male subjects. Various abnormalities 
were found in response to neuroendocrine challenges, uch as the dexametha- 
sone suppression test. In the schizophrenic patients, the authors observed an 
almost 3-fold sleep-related increase in prolactin concentrations a sociated with 
intensified frequency of nocturnal prolactin pulses. This increased stimulatory 
effect of sleep on prolactin secretion became evident immediately after sleep 
onset. In addition, the normal inhibition of cortisol secretion during early sleep 
was absent in the patients with schizophrenia. 
A study by Gil-Ad et al 2 reported abnormal growth hormone response to 
luteinizing hormone-releasing hormone (LHRH) and to thyrotropin-releasing 
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hormone in adolescents with schizophrenia but not in adults with that condi- 
tion. The authors uggested that such responses were the result of the inter- 
action of developmental changes with the disease processes or the lower 
gonadotropin and testosterone concentrations seen in antipsychotic-drug-free 
patients with schizophrenia. 
It has been suggested that serum prolactin concentrations increase in drug- 
naive male and female patients with schizophrenia. 3 In a study by Garver, 4
slightly higher prolactin concentrations were observed in untreated patients 
with acute schizophrenia than in treated patients with chronic schizophrenia or
healthy individuals. Stress has also been associated with transient increases in 
prolactin and cortisol concentrations. 5,6 Higher prolactin and cortisol concentra- 
tions, in turn, might be attributable to the stimulatory effect of serotoninergic 
pathways. 7 
Schizophrenia is a chronic disorder that requires long-term treatment with 
antipsychotic drugs. 8Dopaminergic receptors can be found in cerebral pathways, 
such as the nigrostriatal, tuberoinfundibular, mesolimbic, and mesocortic sys- 
tems. 9Blockade of dopamine receptors in the tuberoinfundibular system stim- 
ulates prolactin release in lactotroph cells. Prolactin secretion is under (the 
influence of) tonic dopaminergic nhibition, which, in turn, is self-regulated by 
negative feedback. Typical antipsychotic drugs such as haloperidol have been 
associated with dose-dependent i creases in prolactin secretion, 1°,11 probably 
due to their primary effect on the pituitary gland, 12,13 which results in the sup- 
pression of sex hormones. 14,15 
Twenty-nine stable patients meeting criteria for schizophrenia or schizo- 
affective disorder were included in an open-label study performed by 
Kirkpatrick et a116 that evaluated prolactin secretion before and after abrupt 
withdrawal of a neuroleptic drug. The findings suggested that basal prolactin 
concentrations were significantly lower on postwithdrawal days 3, 4, and 
5 than on subsequent days. The authors hypothesized that this rebound effect 
is a result of the changes that chronic neuroleptic administration produces in 
the dopaminergic receptors of the tuberoinfundibular system. The study by 
Markianos et a117 assessed prolactin responses to IM haloperidol 5 mg in the 
drug-free state and after 1 month of treatment with neuroleptics in 14 adult 
schizophrenic male patients who had never had drug t eatment and in 20 adult 
schizophrenic male patients who had discontinued neuroleptic treatment for 
2 months to 1 year. The results indicated that after discontinuation of neu- 
roleptic drugs, the hypothalamic-pituitary dopamine receptors may remain 
sensitive for a long time. 
Limited studies investigating hormone concentrations in patients with schizo- 
phrenia have produced inconsistent results. 18-2° Patients with schizophrenia 
might display a variety of hormone profiles. 
Changes in hormone concentrations can affect mood, cognition, and behavior 
and can be the reason for sexual dysfunction and other clinical symptoms. An 
understanding of these mechanisms i  necessary to improve clinical outcomes. 
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The aim of this study was to assess hypothalamic-pituitary-gonadal (HPG)
axis function by comparing serum hormone concentrations from newly admitted 
male patients who were receiving antipsychotic drug treatment for psychotic 
disorders with patients who were antipsychotic-drug-free for the preceding 
6 months. 
PATIENTS AND METHODS 
This cross-sectional study was conducted in 2 acute care public psychiatric 
inpatient units in Brazil--the Pax Clinica Psiqui~trica (Goi~nia) and the Clinica 
Santa Monica (Salvador). The local ethics committees and the ethics committee 
of the Federal University of Silo Paulo approved the study. The study was per- 
formed in accordance to the Declaration of Helsinki. 21 All participating patients 
(or their legal guardians) provided informed written consent. 
All consecutive male patients aged 18 to 55 years admitted uring a 1-year 
period (December 1999 to December 2000) who received a diagnosis of schizo- 
phrenia or related disorders according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, 22 and scored >24 on the Brief Psychiatric 
Rating Scale 23 were eligible for the trial. We did not include women in the study, 
because the concentrations of gonadal hormones would have been affected by 
menstrual cycle phases, pregnancy and childbearing, and menopause. The 
study comprised newly admitted patients that were treated or untreated. 
Treated patients were those receiving treatment with antipsychotic drugs; 
untreated patients were those who had not received any antipsychotic drug for 
the previous 6 months. 
The participants' charts were reviewed to collect data regarding their disor- 
der history. Patients were assessed on admission by attending physicians using 
the Positive and Negative Syndrome Scale (PANSS). 24 On the morning after 
admission, blood samples were collected to determine serum concentrations 
of follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone- 
binding globulin (SHBG), prolactin, free testosterone (FT), and total testoster- 
one (TT). Biochemical analyses of all hormones, with the exception of FT, 
were performed using a Wallac-Delfia 1234/1296 fluorometer (Perkin-Elmer 
Life Sciences Inc., Boston, Massachusetts). FT was measured by radioisoto- 
pic analysis using a Packard-Cobra II auto-gamma counter (Perkin-Elmer Life 
Sciences Inc.). 
Gauss curves were used for displaying the distribution of the serum hor- 
mone concentrations of the treated and untreated patients compared with nor- 
mal concentrations. These normal values were determined by analyzing blood 
samples taken from healthy controls and were provided by a commercial labo- 
ratory (Laborat6rio Fleury, Silo Paulo, Brazil). In addition to radioisotopic 
analysis, the normal FT concentration was also calculated using the serum 
concentrations of TT and SHBG. The normal serum concentrations of FSH, 
LH, and prolactin were determined using values obtained from samples ub- 
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mitted to the laboratory by patients during a 30-day period; samples from 
patients enrolled in clinical studies, those receiving any drugs, and ill patients 
were excluded. 
Statistical Analysis 
The demographic and clinical data for the 2 patient groups were compared 
using the Fisher exact test. Descriptive statistics uch as mean and standard 
deviation were used for describing the hormone data. 
The nonparametric Mann-Whitney test was used for comparing the 2 inde- 
pendent groups of sampled ata, making no assumptions about thedistribution 
of the data. P values were obtained to compare hormone concentrations be- 
tween the 2 patient groups. 25 The Kolmogorov-Smirnov test was used for test- 
ing the equality of distributions of hormone levels of the 2 patient groups com- 
pared with the control groups. 26 Statistical significance was set at P < 0.05 for the 
analysis. 
RESULTS 
Sixty-three male patients (mean [SD] age, 32.9 [9.5] years; range, 18-55 years) 
were included in the study. At admission, 76.2% (48) of the patients were ceiv- 
ing treatment with typical antipsychotic drugs (treated group); 15.9% (10) of these 
were concomitantly using an antidepressant. Fifteen (23.8%) patients had not 
received any antipsychotic or other psychotropic drug (untreated group) for 
_>6 months before admission. The mean (SD) PANSS score for positive symptoms 
for the entire study population was 23.3 (5.9), and the mean (SD) score for nega- 
tive symptoms was 25.4 (5.8); the mean (SD) total PANSS score for the study pop- 
ulation was 101.2 (23.1). The mean (SD) disease duration was 11.4 (9.0) years. 
The only statistically significant differences in demographic characteris- 
tics between the 2 groups was the disease duration, which was significantly 
longer in the untreated group than in the treated group (12.3 [9.7] years vs 7.6 
[8.1] years; P = 0.044) (Table I). 
Control groups were derived from men in the same age range (18-55 years) 
as the study patients who were determined to be healthy and not receiving 
Table I. Demographic and clinical characteristics of treated and untreated male 
patients with schizophrenia (N = 63). 
Patients 
Treated Untreated 
Characteristic (n = 48) (n = 15) P 
Age, mean (SD), y 30.6 (8.9) 36.5 (9.8) 0.064 
Duration of disease, mean (SD), y 7.6 (8.1) 12.3 (9.7) 0.044 
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antipsychotic drugs based on their responses to a questionnaire. SHBG and testos- 
terone data were obtained by measuring samples obtained from 128 Brazilian 
men employed by the laboratory. Serum FSH concentrat ion was based on sam- 
ples from 226 men; LH, 207 men; and prolactin, 1436 men and women. 
Table II shows the mean serum concentrat ions of prolactin, LH, FSH, TT, FT, 
and SHBG for the treated group, the untreated group, and the control groups. 
The treated group had significantly different serum concentrat ions of all hor- 
mones studied compared with the control groups (treated vs control: prolactin, 
24.3 [23.7] pg/L vs 6.8 [0.12] pg/L, P< 0.001; LH, 4.9 [3.4] U/L vs 3.3 [0.13] U/L, 
P = 0.001; FSH, 4.4 [3.9] U/L vs 3.0 [0.06] U/L, P = 0.025; TT, 17.5 [7.8] nmol/L vs 
20.1 [1.64] nmol/L, P = 0.004; FT, 0.056 [0.08] nmol/L vs 0.06 [0.003] nmol/L, P< 
0.001; and SHBG, 33.3 [18.9] nmol/L vs 48.4 [1.45] nmol/L, P= 0.002). The untreated 
group had significantly different mean (SD) values for all hormones except FSH 
and TT (untreated vs control: prolactin, 19.9 [12.8] pg/L vs 6.8 [0.12] pg/L, P = 
0.001; LH, 6.0 [1.9] U/L vs 3.3 [0.13] U/L, P = 0.002; FT, 0.08 [0.04] nmol/L vs 0.06 
[0.003] nmol/L, P= 0.001; and SHBG, 26.6 [11.6] nmol/L vs 48.4 [1.45] nmol/L, P< 
0.001). Serum prolactin concentrat ions were significantly higher in both the 
treated group (P < 0.001) and the untreated group (P = 0.001) when compared 
with the control group. There was no significant difference in prolactin concen- 
tration between the treated and the untreated group. 
In treated patients, although the values of LH concentration (Figure 1) (rela- 
tive dispersion [D] = 0.2568; critical value of D = 0.2349) and FSH concentration 
(Figure 2) (D = 0.4471; critical value of D = 0.2358) were within the normal range, 
they were shifted slightly to the right and had greater dispersion compared with 
untreated patients. 
No differences were found between the TT distribution curve of the controls 
and that of untreated patients (Figure 3). The distribution curve of FT for the 
treated patients was shifted to the left, meaning that those patients had lower 
values than the controls (D = 0.6622; critical value of D = 0.2152). 
Unfortunately, male-only prolactin curves were unavailable for the control 
group. However, patients in the treated and untreated groups had higher serum 
prolactin concentrat ions than the values obtained from the mixed-gender group 
of healthy controls. 
DISCUSSION 
Our results suggest hat serum prolactin concentrat ions did not differ between 
untreated patients and treated patients. Several authors 27-3° have reported nor- 
mal or decreased serum prolactin concentrat ions in drug-naive acute schizo- 
phrenic patients, as well as decreased prolactin concentrat ions in patients with 
chronic schizophrenia without ventricular dilatation. However, elevated serum 
prolactin concentrat ions have been reported after stress. 5,6,31 Therefore, given 
that our study population had acute psychotic symptoms at admission, the 
stress response might be responsible for the increased serum prolactin concen- 
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Luteinizing hormone (LH) distribution curves for psychotic male patients 
receiving drug treatment (treated group), psychotic male patients not 
receiving drug treatment (untreated group), and healthy male controls 
(control group). 
trations observed. On the other hand, in patients with a long history of illness 
who have undergone several previous treatments, the potential exists for the 
hypothalamic-pituitary dopamine receptors to remain sensitized for a long time 
after discontinuation of neuroleptic drugs. 17 
Due to a lack of data (MEDLINE search; key terms: curve, normal distribution, hor- 
mone, drug-free, schizophrenia) on normal distributions of serum hormone concen- 
trations in antipsychotic-drug-free patients with psychotic disorders, we com- 
pared the distribution curves of both treated and untreated patients with those of 
the control groups. We found that only the untreated patients had dispersion of 
hormone concentrations similar to that of the control groups. This supports the 
hypothesis made by Meltzer 32 that such drugs can alter hormone concentrations. 
However, these results might be misleading, because the curves of our matched 
controls might be different from those of a wider population of healthy individuals. 
Serum concentrations of LH and FSH in treated patients uggested iscrete 
shifts to values higher than those measured in the controls. This might be re- 
lated to the slightly lower testosterone concentrations found in patients receiving 
antipsychotic treatment, because LH is responsible for the release of testos- 
terone. When testosterone levels arelow, the pituitary gland releases LH, lead- 
ing to increased production of testosterone in the testicles. 33 
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Figure 2. Follicle-stimulating hormone (FSH) distribution curves for psychotic male 
patients receiving drug treatment (treated group), psychotic male patients 
not receiving drug treatment (untreated group), and healthy male controls 
(control group). 
Stress-related hormones influence reproductive function at 3 sites on the 
HPG axis: in the central nervous ystem, by inhibiting LHRH secretion; in the 
pituitary gland, by interfering with the LHRH-induced release of LH; and in the 
gonads, by altering the stimulating effect of gonadotropins on the secretion of 
sex steroids. 34 Humans exposed to acute stress respond with a small and often 
short-lived increase in plasma LH and testosterone concentrations. 35 The spe- 
cific importance of endogenous testosterone is not fully understood, although 
it might be speculated that testosterone initiates recuperation. 36 
Serum concentrations of FSH and TT in untreated patients were comparable 
to those of the controls, indicating that these hormones might normalize more 
rapidly than the other hormones after treatment is discontinued. This might 
also indicate that the other hormones are altered by the disease itself, or that 
FSH and TT concentrations changed in the untreated patients under stress, 
reaching more normal concentrations, while the treated patients reacted iffer- 
ently or in a less pronounced way to stress. The concentration of FT, which is 
the proportion of testosterone that is biologically active, was decreased in 
treated and untreated patients. 
Analysis of the hormone distribution curves suggested that treated patients 
had greater dispersion than the healthy controls and the untreated patients. 
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Figure 3. Total testosterone (TT) distribution curves for psychotic male patients receiv- 
ing drug treatment (treated group), psychotic male patients not receiving 
drug treatment (untreated group), and healthy male controls (control group). 
This might be explained by the fact that treated patients respond erratically to 
antipsychotic drugs, with great interindividual variation. Variations in response 
might also be the result of differences in regimen compliance. 
Findings regarding prolactin concentrations represent another important re- 
sult of this study. We observed significantly higher serum prolactin concentra- 
tions in untreated patients than in the control groups. Therefore, our findings 
did not corroborate the view that a shift from prolactin-enhancing antipsy- 
chotic drugs to nonprolactin-enhancing atypical drugs is associated with nor- 
malizing prolactin concentrations. Based on our findings, patients who have 
undergone long-term treatment with antipsychotic drugs might experience a 
lower increase in prolactin concentrations over time, leading to lower levels 
overall. Another consideration is that in the acute period of a psychotic disor- 
der, treated patients and untreated patients might have similar prolactin con- 
centrations because cortisol interferes with the prolactin concentration. Thus 
prolactin concentrations in treated and untreated patients might reflect a non- 
specific response to stress. 
The clinical consequences of these findings need to be explored further. An 
interval of time would be required before adopting any drug treatment involv- 
359 
CURRENT THERAPEUTIC RESEARCH 
ing the hormonal system, since the concentration f cortisol and other involved 
hormones are altered during this acute period of the disease. 
There are some limitations to our analyses. Although statistically significant 
differences in serum hormone concentrations were not found between the 
2 study groups, this might have been due to the small sample size (type 2 error). 
It is important to point out hat our antipsychotic-drug-free patients were not 
drug-naive. Therefore, we were unable to determine whether there was a carry- 
over effect associated with a drug that was not specific to psychotic symptoms. 
Because we measured hormone levels during acute episodes of psychotic dis- 
orders, the hormone changes might be associated with stress or to residual 
effects of the drug. In addition, the serum hormone concentration distribution 
curves of patients were compared with those of the controls. The serum hor- 
mone concentration distribution curves of drug-naive patients, which might be 
different, were not assessed in our analyses. Future studies would need to repli- 
cate these findings with a much larger sample size and would also benefit by 
inclusion of a matched control sample. Despite the methodologic limitations, 
we feel that the findings of this study are meaningful for understanding the hor- 
monal physiology and pathophysiology of patients with schizophrenia, s well 
as its clinical consequences. 
CONCLUSIONS 
In this cross-sectional study of patients with acute psychotic disorders, we 
observed that serum prolactin concentrations were significantly higher in pa- 
tients who were ceiving antipsychotic drugs and in antipsychotic-drug-free 
patients than in healthy controls, although we found no difference between the 
2 groups of patients. Despite the fact that concentrations of other hormones 
were within normal ranges in both treated and untreated patients, there was 
greater dispersion in the serum hormone concentration distribution curves of 
patients receiving antipsychotic drugs than those of untreated patients. This 
study supports further investigation of a potential difference in the HPG axis 
between patients with schizophrenia and those who do not have that condition. 
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